This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
"This bill will facilitate trusted university partners to engage in the kinds of research that will best equip state and federal lawmakers and regulators to develop effective cannabis policies based on public health and safety, will allow consumers to make more informed choices, and will help train the next generation of cannabis researchers."
For some perspective on the matter, Project CBD turned to Marc Scialdone, a molecular chemist with Saint Michaels College in Vermont, who co-authored a 2023 paper for the International Cannabinoid Research Society ( ICRS ) entitled The Dark Side of Cannabidiol. Devitt expresses serious safety concerns. “The market crashed.
The Office of Drug Control (ODC) issues several license types, including: Cultivation growing cannabis for medicinal or research purposes. Research studying cannabis for medicinal development. Businesses should also investigate potential research and development (R&D) incentives if applicable.
SPOKANE — Researchers at Washington State University are teaming up with the Puyallup Tribe of Indians in an effort to chart the tribe’s outcomes prescribing medicinal marijuana to patients. This partnership with WSU and Qwibil will help us research the safety and efficacy of cannabis as medicine for our patients’ use.”.
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.
It is quite common for cannabis researchers to make use of vertebrates since animals with spines have an endocannabinoid system (ECS), such as mice and rats. Cats do have an ECS, but why use them for research*? As the team stated, aging cats develop cognitive dysfunction as they become older, much like humans.
Fortunately, Chinese scientists have developed non-hallucinogenic antidepressant compounds. A press release announcing the scientists’ research explains that the team has “designed two new compounds that can relieve depression but do not cause the unwanted effect of hallucination.” A New Kind of Depression Treatment.
Shanita Penny, President of the Minority Cannabis Business Association (MCBA) said , “The Ending Federal Marijuana Prohibition Act of 2019 removes a roadblock impeding criminal justice reform, patient and consumer access, research and innovation.
Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle. .
The lack of research is one of the many reasons that cannabis remains federally illegal. But one of the barriers to conducting the necessary research is its federally illegal status. These intertwining factors plaguing cannabis research must be eradicated for the sake of medical cannabis consumers. .
In an unprecedented move that embraces the evolving landscape of sports health and wellness, the National Football League (NFL) has recently made a significant investment in cannabidiol (CBD) research, aiming to explore its potential as a pain treatment alternative for players suffering from concussions.
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
While many have speculated that the skunk smell could be attributed to the terpenes , or aromatic compounds, of cannabis, the research team behind the study actually discovered a whole new class of volatile sulfur compounds (VSCs) to thank for the cannabis-skunk phenomenon. Studying the Chemical Makeup of Cannabis. Super Skunk. Sour Diesel.
The truth is that total count tests are not a good indicator of cannabis and hemp product safety for the following reasons: Pathogenic microbes may still be present Testing methods often do not agree Growers are discouraged from using beneficial microbes Growers are encouraged to use remediation. fumigatus, A.
Public Safety (PS) is supporting efforts to enforce the legalization and regulation of cannabis through activities to deter criminal activity and to help ensure that organized crime does not penetrate the legalized system. PS is working with the PTs and other key stakeholders (e.g.,
(NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. About cbdMD, Inc. cbdMD, Inc.
The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company. . – July 28, 2021) – PharmaDrug Inc.
From 1994 to 2013, he was employed as a principal investigator at DuPont Central Research and Development. with unknown pharmacological and safety profiles.” End cannabis prohibition, the market for these products will go away and these compounds will be relegated to research labs, where they belong, not the marketplace.
Our outdated laws have ruined lives, devastated communities, and wasted resources for critical medical treatment and research. The enactment of these policies have not negatively impacted workplace safety , crime rates , traffic safety , or youth use patterns. ” Said Rep.
There is little relationship between blood or saliva limits on cannabis-impaired driving and the driver’s actual impairment, and law enforcement authorities must develop new detection methods, according to the findings of a new study. They also found that even 3.5 A ‘pressing need’ for better cannabis intoxication, impairment tests.
The National Academies of Sciences reports that PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. The psychological symptoms that develop because of the trauma affect mood, cognition, memories (both suppression and the inability to form new memories) and physical health.
(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.
NM: As someone who has been researching cannabis for decades, how do you feel about the current legalization situation worldwide and in Japan, in particular? Dr. Andrew Weil: I think the trend very clearly is that in most developed countries, cannabis is being made legal first for medical uses and then also for recreational uses.
Patients are looking to their medical providers for information on cannabis safety, potential for interactions with pharmaceuticals, and therapeutic applications. However, the existing legal environment significantly hinders the ability of clinicians to engage with cannabis research or offer clear guidance. lags behind other nations.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.
Biotech startup to bring safety and efficacy to the emerging psychedelic industry, brings on University of Michigan Researcher as Chief Science Officer. Nearly all forms of research being done on psychedelics are via the digestive tract, which slows uptake, requires higher dosage, and may lead to harmful side effects in the body.
We don’t want to see research fall to the wayside as it has for cannabis, both in Canada and globally. We are in a mental health crisis and its critical to ensure that we conduct clinical trials to demonstrate safety, and efficacy up to and including phase 3 large scale clinical trials.
This explosion of interest in the use of cannabis and CBD for animals has led to the development of a multi-million dollar industry creating cannabis-based products for pets. In response, veterinarians and others concerned for patient safety promoted a change in state law. Related story.
She is currently a law school professor teaching Marijuana and the Law at California Western School of Law and researcher under a contract with NHTSA and NORC on the topic of the prosecution of drugged driving cases. There are newly developing alternative testing devises that use oral fluid and drug breathalyzers.
Researchers followed chronic pain patients and found something fascinating: the group using just 2.5 A leading researcher in cannabis medicine documented something fascinating called the “biphasic effect.” With cannabis, we’re talking about tiny amounts maybe 1 to 5 milligrams of THC, sometimes even less.
SciSparc intends to evaluate the efficacy, safety and tolerability of its Proprietary Cannabinoid-Based Treatment- SCI-110. The company has begun preparation that will facilitate the commencement of the clinical study and engaged with a contract research organization (CRO) to provide support for the trial.
According to an August 2019 report released by Grand View Research, Inc., We’ll continue to update you on any other regulatory development via this blog. As the first national retailer to adopt CBD guidelines, Sephora is raising the need to assist consumers in navigating this complex regulatory landscape.
Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. Validcare contracted with 17 CBD companies and acted as the Contract Research Organization, which included gaining feedback from FDA on the protocol, conducting the study and publishing its results.
Psilocybin has been in the news with increasing frequency as research into psychedelic therapy has proliferated, and a number of local jurisdictions, including the cities of Oakland, Denver , and Santa Cruz have decriminalized psilocybin to varying degrees. There is a possibility for local jurisdictions to “opt out.”.
Let’s take a closer look at this new research around CBD for Cerebral Palsy and examine the extent of this trend and its implications for the future of CP management. It occurs due to abnormalities or damage to the developing brain before, during, or after birth. What is Cerebral Palsy?
NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study abstract is available here. The methods for both phases were the same.
But for now, the developers are focused on creating a training that emphasizes compassionate response, de-escalation, and the safety and well-being of individuals having a challenging time with a psychedelic experience. Interesting piece from Lucid news. Read the full report at .
Cannabis research related to PTSD (post-traumatic stress disorder) is a growing field. We continue to learn more and more as research funding is becoming available and laws are allowing for more studies to be conducted. Some researchers hypothesize that cannabis could potentially help modulate this system to alleviate PTSD symptoms.
According to UC Berkeley’s Department of Environmental Science Policy and Management researchers, California’s cannabis crops are threatened by wildfires more than any other crop. . UC Berkeley researchers assessed the level of wildlife risk faced by licensed cannabis farms in 11 counties that produce the plant in large quantities.
Rather, it’s a modest bipartisan piece of legislation that’s simply meant to promote research into marijuana. JUST IN: The Senate passed my bill with Senators Grassley and Schatz to cut red tape around the research process of marijuana and marijuana-derived medications. — Senator Dianne Feinstein (@SenFeinstein) March 24, 2022.
At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. The company is scaling its proprietary research and development methods in order to become one of the first to produce and bring to market psilocybin-based treatments.
Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Once known solely as a party drug, ketamine is starting to earn a new reputation thanks to research efforts into its potentially medicinal qualities.
However, research on the specific benefits and effects of THCjd is still in the works. However, due to its legal status and limited research, it is necessary to exercise caution and comply with local regulations when considering its use. It’s also worth mentioning that the safety of THCjd depends on various factors.
Position Summary: Reporting to Operations Manager, the Cannabis & Controlled Substances Officer (CCBO) will inspect various teaching, diagnostic and research facilities of the University. Provide advice and safety training sessions to the community on safe handling, use and disposal of cannabis and/or controlled substances.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content